• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    23Andme Holding Co. (NQ: ME )

    0.3137 -0.0091 (-2.82%)
    Streaming Delayed Price Updated: 11:36 AM EDT, Aug 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about 23Andme Holding Co.

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Why 23andMe Holding Stock Plummeted by 13% Today
    Investors reacted sharply and not well to the company's inaugural set of fiscal 2024 earnings. 
    Via The Motley Fool
    23andMe Reports FY2024 First Quarter Financial Results
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe to Report FY2024 First Quarter Financial Results
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe Holding's Return On Capital Employed Overview
    Via Benzinga
    Recap: 23andMe Holding Q4 Earnings
    Via Benzinga
    23andMe Holding's Earnings Outlook
    Via Benzinga
    23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
    With millions of Americans experiencing mental health symptoms, 23andMe+ members now have exclusive access to four mental health reports to help determine their genetic likelihood of having one of... 
    From 23andMe, Inc.
    Via GlobeNewswire
    3 Gene Testing Stocks to Buy Before They Take Off
    The future of gene testing is bright thanks to an aging population. Here are three companies leading the industry. 
    Via InvestorPlace
    23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
    From 23andMe, Inc.
    Via GlobeNewswire
    Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
    Neither has a traditional business model, but that could be an asset for both. 
    Via The Motley Fool
    3 Key Biotech Trends for 2023 And Beyond
    New opportunities are becoming apparent, but so are fresh risks in the biotech field. 
    Via The Motley Fool
    Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich … or Broke.
    Explore the world of high-risk penny stocks, with their potential for significant returns, as we analyze three speculative opportunities. 
    Via InvestorPlace
    New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
    From 23andMe, Inc.
    Via GlobeNewswire
    3 Personalized Medicine Stocks to Buy for Long-Time Returns
    Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out. 
    Via InvestorPlace
    23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
    From 23andMe Holding Co.
    Via GlobeNewswire
    23andMe Releases New Report Revealing Likelihood of Developing Lupus
    23andMe+ members can now gain insights on the chronic autoimmune condition 
    From 23andMe Holding Co.
    Via GlobeNewswire
    Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
    Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategy 
    From 23andMe Holding Co.
    Via GlobeNewswire
    BELLUS Health, Sunrun And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
    U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
    Via Benzinga
    23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
    From 23andMe Holding Co.
    Via GlobeNewswire
    Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
    From 23andMe Holding Co.
    Via GlobeNewswire
    23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
    Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers 
    From 23andMe Holding Co.
    Via GlobeNewswire
    3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks
    Biotechs with an AI strategy are likely to be the first to flourish from the disruptions. 
    Via The Motley Fool
    23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
    Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented 
    From 23andMe Holding Co.
    Via GlobeNewswire
    AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023
    They've been using machine learning for years, and now they might do even more. 
    Via The Motley Fool
    New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
    From 23andMe Holding Co.
    Via GlobeNewswire
    2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise
    There's nothing better than getting a bargain that'll pay off for years. 
    Via The Motley Fool
    2 High-Growth Stocks That Could Double Your Money in 5 Years or Less
    Both are likely to double quite soon, and they aren't even that risky. 
    Via The Motley Fool
    23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
    The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and... 
    From 23andMe Holding Co.
    Via GlobeNewswire
    23andMe to Present at Upcoming Investor Conferences
    From 23andMe Holding Co.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.